Rutgers University entered into an exclusive license with Everist Genomics Inc., headquartered in Ann Arbor Michigan for patents covering a novel technology. This technology makes it possible to receive early measurements on various vascular conditions especially on patients with no obvious symptoms.
Gary M Drzewiecki, Professor in the Department of Biomedical Engineering developed the technology. “The accuracy and clinical relevance of the available non-invasive measurement techniques has been a challenge until now,” Drzewiecki said. “Our approach for analyzing arterial and endothelial function data provides a unique means for diagnosis and monitoring at the point-of-care.
Everist Genomics intends to develop and commercialize products based on the Rutgers’ patents using the AngioDefender device platform. The system uses non-invasive sensor technology and a sophisticated software algorithm to rapidly provide physicians with data that can help detect early stage cardiovascular disease.
The entire AngioDefender procedure is completed in less than 15 minutes and the system transmits 25 components of information, including relevant elements of the patient record and CVD diagnostic data to a desk-top computer, laptop, notebook, or tablet.
According to Alex Charlton, Executive Vice Chairman of the company, “This low cost test using Rutgers technology is already gaining acceptance in the Indian market where the company has partnered with the Manipal Group, a major healthcare provider. Charlton reports that Everist is installing AngioDefenders in the Middle East and has regulatory approval to introduce the product to 27 European countries.
For further information on technology commercialization at Rutgers, go to http://otc.rutgers.edu. For partnership opportunities related to AngioDefender, email Vicki Theisen, General Manager, Everist Genomics, Inc. at vt@everistgenomics.com.
